Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapy for lower-risk MDS.

Hematology. American Society of Hematology. Education Program - 4 Dec 2020

Carraway Hetty E, Saygin Caner

Abstract excerpt

Lower-risk myelodysplastic syndromes (MDS) are characterized by the presence of dysplasia, low bone marrow blast percentage, low number and depth of cytopenia(s), and relatively good-risk karyotpic and molecular abnormalities. A score of ≤3.5 on the Revised International Prognostic Scoring System classifies patients as lower-risk MDS. Information from a mutational profile of the MDS at time of diagnosis (and over...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Activin Receptors, Type II
Share to Anemia
Share to Blood Transfusion

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoglobulin Fc Fragments

Share to Lenalidomide

Share to Receptors, Fc

Share to Thrombocytopenia

Share to Thrombopoietin

Source

Open in PubMed Open full text

Identifiers

PMID: 33275714
DOI: 10.1182/hematology.2020000127
PMCID: PMC7727572

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapy for lower-risk MDS.PMID 33275714Read ↗

Lowering the boom on lower-risk myelodysplastic syndromes.Semantic proximity Read ↗

Current therapeutic approaches for patients with myelodysplastic syndromes.Semantic proximity Read ↗

Advances in the management of higher-risk myelodysplastic syndromes: future prospects.Semantic proximity Read ↗

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.Semantic proximity Read ↗

How I treat higher-risk MDSSemantic proximity Read ↗

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Semantic proximity Read ↗

Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS.Semantic proximity Read ↗

Myelodysplastic syndromes: Updates on Genomic Landscape, Molecular Subtypes, & Targeted Therapies.Semantic proximity Read ↗

Myelodysplastic Neoplasms (MDS): The Current and Future Treatment LandscapeSemantic proximity Read ↗

Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study.Semantic proximity Read ↗

Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?Semantic proximity Read ↗

Myelodysplastic Syndromes: A New Decade.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.